PubMed:10390212 JSONTXT

{"project":"PMID_GLOBAL","denotations":[{"id":"T1","span":{"begin":78,"end":87},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T2","span":{"begin":90,"end":105},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T3","span":{"begin":142,"end":151},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T4","span":{"begin":239,"end":248},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T5","span":{"begin":599,"end":609},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":628,"end":637},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":1547,"end":1556},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":1598,"end":1607},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0005812"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"0005108"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"0005812"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"0005812"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0005550"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0005812"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0005550"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0005812"}],"text":"Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.\nZanamivir is a potent inhibitor of influenza A and B virus neuraminidases and is active topically in experimental and natural human influenza. We conducted this double-blinded, placebo-controlled study to evaluate the safety and efficacy of intravenously administered zanamivir. Susceptible volunteers were randomized to receive either saline or zanamivir (600 mg) intravenously twice daily for 5 days beginning 4 h prior to intranasal inoculation with approximately 10(5) 50% tissue culture infectious doses (TCID50) of influenza A/Texas/36/91 (H1N1) virus. Reductions in the frequency of viral shedding (0% versus 100% in placebo, P \u003c 0.005) and seroconversion (14% versus 100% in placebo, P \u003c 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50. day/ml in placebo, P \u003c 0.005) were observed in the zanamivir group, as were reductions in fever (14% versus 88% in placebo, P \u003c 0.05), upper respiratory tract illness (0% versus 100% in placebo, P \u003c 0.005), total symptom scores (1 versus 44 [median] in placebo, P \u003c 0.005), and nasal-discharge weight (3.9 g versus 17.5 g [median] in placebo, P \u003c 0.005). Zanamivir was detectable in nasal lavage samples collected on days 2 and 4 (unadjusted median concentrations, 10.5 and 12.0 ng/ml of nasal wash, respectively). This study demonstrates that intravenously administered zanamivir is distributed to the respiratory mucosa and is protective against infection and illness following experimental human influenza A virus inoculation."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":275,"end":282},"obj":"HP_0000618"},{"id":"T2","span":{"begin":989,"end":994},"obj":"HP_0001945"}],"text":"Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.\nZanamivir is a potent inhibitor of influenza A and B virus neuraminidases and is active topically in experimental and natural human influenza. We conducted this double-blinded, placebo-controlled study to evaluate the safety and efficacy of intravenously administered zanamivir. Susceptible volunteers were randomized to receive either saline or zanamivir (600 mg) intravenously twice daily for 5 days beginning 4 h prior to intranasal inoculation with approximately 10(5) 50% tissue culture infectious doses (TCID50) of influenza A/Texas/36/91 (H1N1) virus. Reductions in the frequency of viral shedding (0% versus 100% in placebo, P \u003c 0.005) and seroconversion (14% versus 100% in placebo, P \u003c 0.005) and decreases in viral titer areas under the curve (0 versus 11.6 [median] log10 TCID50. day/ml in placebo, P \u003c 0.005) were observed in the zanamivir group, as were reductions in fever (14% versus 88% in placebo, P \u003c 0.05), upper respiratory tract illness (0% versus 100% in placebo, P \u003c 0.005), total symptom scores (1 versus 44 [median] in placebo, P \u003c 0.005), and nasal-discharge weight (3.9 g versus 17.5 g [median] in placebo, P \u003c 0.005). Zanamivir was detectable in nasal lavage samples collected on days 2 and 4 (unadjusted median concentrations, 10.5 and 12.0 ng/ml of nasal wash, respectively). This study demonstrates that intravenously administered zanamivir is distributed to the respiratory mucosa and is protective against infection and illness following experimental human influenza A virus inoculation."}